The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance(®)), ameliorates glucotoxicity via excret...

Descripción completa

Detalles Bibliográficos
Autores principales: Steven, Sebastian, Oelze, Matthias, Hanf, Alina, Kröller-Schön, Swenja, Kashani, Fatemeh, Roohani, Siyer, Welschof, Philipp, Kopp, Maximilian, Gödtel-Armbrust, Ute, Xia, Ning, Li, Huige, Schulz, Eberhard, Lackner, Karl J., Wojnowski, Leszek, Bottari, Serge P., Wenzel, Philip, Mayoux, Eric, Münzel, Thomas, Daiber, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491464/
https://www.ncbi.nlm.nih.gov/pubmed/28667906
http://dx.doi.org/10.1016/j.redox.2017.06.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491464/
https://www.ncbi.nlm.nih.gov/pubmed/28667906
http://dx.doi.org/10.1016/j.redox.2017.06.009

Ejemplares similares